Science

The Key To HIV: Gilead Sciences, To Develop Drugs For HIV And NASH, Details Inside

By Sai , Jan 13, 2017 08:27 PM EST
Close
VMAs 2017: What to expect

With HIV being considered as one of the long dreaded diseases, experts have yet found the appropriate solution to the problem. Until recently, as Gilead Sciences Inc. (GILD) CEO John Milligan started his presentation at the 35th annual J.P. Morgan Healthcare Conference in San Francisco, together with the investors of the said biopharmaceutical company, it was revealed that they will be starting to launch a project that aims to put emphasis on Hepatitis C, NASH and HIV. Authorities have also revealed that the company will be spending as much as $31.6 billion to show their support in putting an end to these diseases.

Gilead Sciences, To Develop Drugs For HIV And NASH

According to reports revealed by Drug Discovery And Development, the money that will be spent will allegedly be used to support 12 new HIV cure research projects. The series of projects are said to be initiated by the country's leading academic institutions, non-profit organizations and community groups from across the globe, which focuses on three key areas namely, translational research, efficacy studies in animal models and community perspectives of HIV cure. Executive Vice President, Research, Gilead Sciences William Lee, PhD, said that considering their experience gained throughout the years in addressing the issue of HIV/AIDS, they highlighted the fact that there is no one-size-fits-all solution. However, it was found that the company is in fact, excited about the potential of these projects and is looking forward to seeing the results and all the learnings that will be incorporated to it.

Meanwhile, as per Investopedia, Milligan is reportedly optimistic about Gilead's HIV product portfolio. However, the current HIV drugs which are making good revenues for Gilead are based on tenofovir disoproxil fumarate (TDF) medication, which Milligan believes is dying out. In line with it, it was found that the company will now be switching its focus into alternative tenofovir alafenamide (TAF)-based HIV drugs, which include Genvoya, Descovey, and Odefsey drugs. Ultimately, authorities from the said company have highly emphasized that they were recently announced as one of the foremost corporate providers of philanthropic support to address HIV/AIDS by the Funders Concerned About AIDS (FCAA) organization.

              

Related Articles

© 2017 ITECHPOST, All rights reserved. Do not reproduce without permission.
Real Time Analytics